---
title: "BUZZ-PepGen, Dyne rise after Novartis' $12 bln deal to buy rival Avidity"
description: "Shares of PepGen rose 21% to $5.53, while Dyne Therapeutics surged 37.5% to $23.54 following Novartis' $12 billion acquisition of Avidity Biosciences. Both companies are developing treatments for rare"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262933544.md"
published_at: "2025-10-27T15:24:34.000Z"
---

# BUZZ-PepGen, Dyne rise after Novartis' $12 bln deal to buy rival Avidity

> Shares of PepGen rose 21% to $5.53, while Dyne Therapeutics surged 37.5% to $23.54 following Novartis' $12 billion acquisition of Avidity Biosciences. Both companies are developing treatments for rare muscle disorders. RBC Capital Markets predicts Dyne will trade significantly higher due to its similar platform to Avidity, which has a market cap of $2.4 billion. Year-to-date, Dyne is up 1.8% and PepGen has increased 47.8%.

Shares of drug developer PepGen (PEPG.O) up 21% at $5.53, while Dyne Therapeutics (DYN.O) rise 37.5% at $23.54 Rival Avidity Biosciences (RNA.O) on Sunday agreed to be acquired by Swiss drugmaker Novartis (NOVN.S) for about $12 billion in cash to bolster its portfolio of treatments for rare muscle disorders

Pepgen and Dyne are also currently developing drugs to treat rare muscle disorders such as myotonic dystrophy type 1

“We anticipate DYN to trade materially higher tomorrow given similar platform, not materially behind RNA and $2.4b cap”- RBC Capital Markets

Including session moves, DYN up 1.8% and PEPG up 47.8% YTD

### Related Stocks

- [DYN.US - Dyne Therapeutics](https://longbridge.com/en/quote/DYN.US.md)
- [PEPG.US - PepGen](https://longbridge.com/en/quote/PEPG.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Dyne Therapeutics: Positioned for Growth in the RNA Therapeutics Market Amid Industry Validation | Francois Brisebois has issued a Buy rating for Dyne Therapeutics, citing the recent $12 billion acquisition of Avidity B | [Link](https://longbridge.com/en/news/262941348.md) |
| BUZZ-PepGen shares more than double after muscle disease drug shows promise in trial | Shares of PepGensurged 130% to $6.10 in premarket trading after the company announced promising results from its early-s | [Link](https://longbridge.com/en/news/258849411.md) |
| Significant opportunities exist in the global pain market for novel mechanisms and modalities | The global pain market presents significant opportunities for innovation, particularly in developing non-addictive alter | [Link](https://longbridge.com/en/news/275921122.md) |
| Circio Grants Broad Employee Stock Options After NOK 70m Fundraise | Circio Holding ASA has launched a stock option program for employees, issuing 5 million options after raising NOK 70 mil | [Link](https://longbridge.com/en/news/275972910.md) |
| Avidity Biosciences, Inc. $RNA Shares Acquired by Candriam S.C.A. | Candriam S.C.A. increased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA) by 10.2% in Q3, owning 487,917 shares valu | [Link](https://longbridge.com/en/news/275451342.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
